Syndax Pharmaceuticals SNDX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -102.8%+684pp | -158.2%— | -275.1%— | -433.7%— | -786.6%— | |
| Net margin | -111.9%+646pp | -165.4%— | -279.3%— | -428.5%— | -757.5%— | |
| Returns | ||||||
| Return on equity | -189.5%-95.8pp | -161.8%-86.1pp | -129.3%-47.4pp | -113.2%-49.9pp | -93.7%-41.8pp | |
| Return on assets | -43.7%+12.3pp | -45.5%+2.2pp | -63.7%+8.3pp | -62.4%-4.3pp | -56%-8.0pp | |
| Return on invested capital | -67.9%+20.8pp | -50.3%+13.5pp | -109.6%+18.7pp | -95.5%-4.8pp | -88.6%-19.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×+0.3× | 0.3×+0.2× | 0.2×+0.2× | 0.1×+0.1× | 0.1×— | |
| Liquidity | ||||||
| Current ratio | 5.5×-0.3× | 4.4×-1.4× | 4.6×-2.3× | 4.7×-5.8× | 5.8×-3.1× | |
| Quick ratio | 5.1×-0.7× | 4.1×-1.7× | 4.4×-2.6× | 4.5×-6.0× | 5.8×-3.2× | |
| Cash ratio | 1.5×-0.1× | 1.1×-0.4× | 1×-1.2× | 1×-1.5× | 1.6×-0.6× | |
| Leverage | ||||||
| Debt-to-equity | 8.4×+6.9× | 5.4×+3.1× | 2.8×+2.8× | 2.1×+2.1× | 1.6×+1.6× | |
| Debt-to-assets | 0.7×+0.2× | 0.7×-0.3× | 0.6×+0.6× | 0.6×+0.6× | 0.5×+0.5× | |
| Per Share | ||||||
| Book value per share | $0.47-81.1% | $0.75-77.8% | $1.33-68.9% | $1.82-64.2% | $2.50-56.8% | |
| Valuation | ||||||
| Market capitalization | $2.06B+95.0% | $1.83B+61.8% | $1.33B-19.3% | $793.36M-54.7% | $1.06B-38.8% | |
| Enterprise value | $2.28B+84.0% | $2.04B+24.2% | $1.54B+1.8% | $1.02B-38.3% | $1.24B-23.2% | |
| Price / sales | 9.5×-14.7× | 10.6×— | 11.9×— | 10.1×— | 24.2×— | |
| Price / book | 49.5×+44.6× | 28.3×+24.3× | 11.5×+7.0× | 5×+1.0× | 4.9×+1.4× | |
| EV / sales | 10.5×-17.9× | 11.8×— | 13.8×— | 13×— | 28.3×— | |
| Earnings yield | -11.8%+19.5pp | -15.6%+12.6pp | -23.5%-5.4pp | -42.2%-27.1pp | -31.3%-17.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Syndax Pharmaceuticals's ratios come from?
- Every ratio is computed from Syndax Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.